This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PIRS Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock About Pieris Pharmaceuticals Stock (NASDAQ:PIRS) 30 days 90 days 365 days Advanced Chart Get Pieris Pharmaceuticals alerts:Sign Up Key Stats Today's Range$13.26▼$15.3550-Day Range$13.60▼$17.0752-Week Range$6.20▼$18.68Volume51,728 shsAverage Volume64,171 shsMarket Capitalization$17.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.Read More… Pieris Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScorePIRS MarketRank™: Pieris Pharmaceuticals scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pieris Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pieris Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pieris Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPieris Pharmaceuticals has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PIRS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPieris Pharmaceuticals does not currently pay a dividend.Dividend GrowthPieris Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.01 Short InterestThere is no current short interest data available for PIRS. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Pieris Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pieris Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.39% of the stock of Pieris Pharmaceuticals is held by insiders.Percentage Held by Institutions40.11% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pieris Pharmaceuticals' insider trading history. Receive PIRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PIRS Stock News HeadlinesPieris Pharmaceuticals IncApril 19, 2025 | money.usnews.comPalvella Therapeutics Inc (PVLA)December 27, 2024 | investing.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.April 26, 2025 | Stansberry Research (Ad)Main Line biotech firm completes reverse merger, raises $78.9 millionDecember 17, 2024 | bizjournals.comOne new option listing and one option delisting on December 16thDecember 17, 2024 | markets.businessinsider.comPalvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease TreatmentsDecember 14, 2024 | msn.comPalvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 MillionDecember 14, 2024 | markets.businessinsider.comPIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRSNovember 20, 2024 | businesswire.comSee More Headlines PIRS Stock Analysis - Frequently Asked Questions How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($19.20) EPS for the quarter, hitting the consensus estimate of ($19.20). The biotechnology company earned $4.06 million during the quarter, compared to analysts' expectations of $7.98 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 80.93% and a negative net margin of 39.71%. When did Pieris Pharmaceuticals' stock split? Pieris Pharmaceuticals's stock reverse split on Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Adobe (ADBE), GE Aerospace (GE) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/02/2021Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PIRS CIK1583648 Webwww.pieris.com Phone(857) 246-8998Fax49-8161-141-1444Employees140Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($12.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,540,000.00 Net Margins-39.71% Pretax Margin-1,179.96% Return on Equity-80.93% Return on Assets-59.55% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual Sales$42.81 million Price / Sales0.42 Cash FlowN/A Price / Cash FlowN/A Book Value$21.66 per share Price / Book0.63Miscellaneous Outstanding Shares1,320,000Free Float1,236,000Market Cap$17.95 million OptionableOptionable Beta0.61 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:PIRS) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.